Healthcare Industry News:  BioMimetic Therapeutics 

Devices Personnel

 News Release - July 6, 2007

MAKO Surgical Corp. Names Charles W. Federico to Board of Directors

FORT LAUDERDALE, Fla., July 6 (HSMN NewsFeed) -- MAKO Surgical Corp., a developer of minimally invasive, robotic-enabled techniques for knee surgery, announced today that Charles W. Federico has been named to the company's Board of Directors, effective June 5.

Federico has more than 32 years experience in the medical device industry and most recently served as Group President and Chief Executive Officer of Orthofix N.V., a recognized leader in minimally invasive orthopedic and trauma surgical devices. Federico remains a director at Orthofix and also serves as a trustee on the prestigious Orthopaedic Research and Education Foundation.

"We are extremely pleased to have Charles Federico join our Board of Directors," said MAKO Surgical Corp. President and CEO Maurice R. Ferre, M.D. "His knowledge and reputation are second to none within the orthopedic medical device industry, and we feel he will bring tremendous value and insights to MAKO."

Prior to joining Orthofix in 1996, Federico was President of Smith & Nephew Endoscopy, formerly known as Dyonics, Inc, a top arthroscopic surgical instrumentation company. He also served as Vice President, Director of Marketing and General Manager of Dyonics and has held numerous management and marketing positions with General Foods Corporation, Puritan Bennett Corporation and LSE Corporation. In addition, he currently serves on the boards of SRI/Surgical Express, Inc. and BioMimetic Therapeutics, Inc.

About MAKO Surgical Corporation

MAKO Surgical Corp. is a privately held, emerging orthopedic medical device company developing advanced solutions for less invasive knee surgery. Founded in November 2004, the company has developed and released the MAKO Haptic Guidance System(TM) (HGS(TM)). This FDA-cleared, physician-interactive robotic system allows surgeons to provide an innovative tissue-sparing bone resurfacing therapy called MAKOplasty(TM) to a large, yet significantly underserved patient population suffering from early to mid stage degenerative joint disease of the knee. MAKOplasty(TM) empowers orthopedic surgeons to improve patient outcomes, shorten recovery time and enhance post-operative lifestyle. To date, the company has performed more than fifty MAKOplasty(TM) procedures in support of unicondylar knee arthroplasty. MAKO's proprietary technology is protected by more than 250 patents and patent applications in the areas of robotics, haptics, robotic surgery, image guided surgical navigation, implants and materials. For more information, please visit

Source: MAKO Surgical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.